Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Disc Medicine, Inc. has announced an upsized underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $225 million to support its clinical development and commercialization efforts for hematologic diseases [1][2]. Group 1: Offering Details - Disc is selling 2,619,049 shares of common stock at $84.00 per share and pre-funded warrants to purchase 59,523 shares at $83.9999 each, with gross proceeds expected to be around $225 million [1]. - The Selling Stockholder, AI DMI LLC, is selling 297,619 shares, expecting to raise approximately $25 million [1]. - Underwriters have a 30-day option to purchase an additional 446,428 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), funding research and clinical development of current or additional product candidates, and for general corporate purposes [2]. Group 3: Underwriters - Jefferies, Leerink Partners, Morgan Stanley, and Cantor are acting as joint book-running managers for the offering, while Wedbush PacGrow and H.C. Wainwright & Co. are co-managers [3]. Group 4: Regulatory Information - The offering is made pursuant to an automatic shelf registration statement filed with the SEC, and a final prospectus supplement will be available on the SEC's website [4].